| Basics |
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.
|
| IPO Date: |
April 9, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$830.48M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 2.95%
|
| Avg Daily Range (30 D): |
$0.39 | 2.95%
|
| Avg Daily Range (90 D): |
$0.35 | 2.66%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.26M |
| Avg Daily Volume (30 D): |
1.35M |
| Avg Daily Volume (90 D): |
1.06M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
81 |
| Avg Trade Size (Sh.) (90 D): |
73 |
| Institutional Trades |
| Total Inst.Trades: |
961 |
| Avg Inst. Trade: |
$1.45M |
| Avg Inst. Trade (30 D): |
$1.32M |
| Avg Inst. Trade (90 D): |
$1.43M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.47M |
| Avg Closing Trade (30 D): |
$1.41M |
| Avg Closing Trade (90 D): |
$1.71M |
| Avg Closing Volume: |
101.97K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q1 2026 |
|
Basic EPS
|
|
$-.92
|
$-1.12
|
|
Diluted EPS
|
|
$-.92
|
$-1.12
|
|
Revenue
|
$
|
$ 13.7M
|
$ 1.4M
|
|
Gross Profit
|
$
|
$ 12.47M
|
$
|
|
Net Income / Loss
|
$
|
$ -49.48M
|
$ -60.1M
|
|
Operating Income / Loss
|
$
|
$ -46.05M
|
$ -59.01M
|
|
Cost of Revenue
|
$
|
$ 1.23M
|
$
|
|
Net Cash Flow
|
$
|
$
|
$ -10.03M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 22, 2016:
1:14
|
|
|
|
